What happened
On March 19, 2026 the FDA approved Wegovy HD, a 7.2 mg weekly semaglutide injection, for adults with obesity or with overweight plus at least one weight-related condition. The decision came 54 days after the filing and was the fourth product cleared under the Commissioner's National Priority Voucher pilot.
The FDA said the higher dose produced more average weight reduction than earlier approved doses, with a safety picture in line with known semaglutide effects. In people who also had type 2 diabetes, blood-sugar lowering looked similar to the lower dose. Common side effects were gastrointestinal. Altered skin sensation was more frequent at 7.2 mg than at lower doses, usually eased on its own or after a dose cut, and the agency said it is still looking at that reaction. The label keeps the class boxed warning about thyroid C-cell tumors from rodent studies.
Novo Nordisk's same-day release added STEP UP trial figures that the FDA notice does not list. In 1,407 adults with BMI of 30 or higher and no diabetes, people assigned to 7.2 mg lost 20.7% of body weight at 72 weeks if everyone stayed on treatment, versus 17.5% on 2.4 mg and 2.4% on placebo. Counting people whether or not they stayed on the shot, the company reported 18.8% versus 15.5% versus 3.9%. About 31% on the high dose reached at least 25% loss. Novo says the high dose is for adults who already tolerated 2.4 mg for at least four weeks and still need more loss.
What it means
A person already on Wegovy 2.4 mg can ask a clinician whether a higher weekly shot is appropriate, and what extra skin or gut effects to watch. This is still semaglutide, not a new mechanism. Coverage, supply, and the cash price are separate from the approval.
The FDA write-up does not give the 7.2 mg shot the cardiovascular-risk language that already sits on the 2.4 mg injection. Do not assume the new dose inherited every older indication.
What it does not mean
It is not a recommendation to jump from another GLP-1 to 7.2 mg. It is not proof that the high dose beats tirzepatide or surgery. Company STEP UP percentages are trial averages, not a personal forecast. It is not a compounding or gray-market pathway.
Sources
- 1. FDA, March 19, 2026 approval of higher-dose semaglutide (Wegovy HD)
- 2. Novo Nordisk, March 19, 2026 manufacturer release with STEP UP table
Related guide
GLP-1 medications Information Center hub
Related discussion
GLP-1 Weight Loss Medications forum
Educational information only. Not medical advice. Do not start, stop, or change treatment from this brief.